Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.

Journal of cutaneous pathology - 1 Nov 2020

Tabata Mika M, Chase Melissa, Kwong Bernice Y, Novoa Roberto A, Fernandez-Pol Sebastian

Abstract excerpt

We report a case of differentiation syndrome in a patient receiving the IDH1 inhibitor ivosidenib, with skin biopsy showing isocitrate dehydrogenase (IDH) R132H-mutated leukemia cutis. A 72-year-old man with IDH1-mutated acute myeloid leukemia (AML), status-post allogeneic cell transplantation, on ivosidenib for 6 months, was admitted for culture-negative neutropenic fever, pink and purpuric plaques and patches...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Pyridines

Share to Syndrome

Source

Identifiers

PMID: 32588467
DOI: 10.1111/cup.13780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.PMID 32588467Read ↗

IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.Semantic proximity Read ↗

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.Semantic proximity Read ↗

Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.Semantic proximity Read ↗

Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.Semantic proximity Read ↗

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.Semantic proximity Read ↗

Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.Semantic proximity Read ↗

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.Semantic proximity Read ↗

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.Semantic proximity Read ↗

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.Semantic proximity Read ↗

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.Semantic proximity Read ↗

Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.